These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35710310)

  • 1. Pretreatment attrition and treatment initiation delay among rifampicin-resistant tuberculosis patients in Lagos, Nigeria: a retrospective cohort study.
    Adejumo OA; Daniel O; Adepoju VA; Onoh MO; Sokoya OD; Abdur-Razzaq H; Moronfolu O; Oyadotun OM; Olusola-Faleye B
    Trans R Soc Trop Med Hyg; 2022 Dec; 116(12):1154-1161. PubMed ID: 35710310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria.
    Adejumo OA; Olusola-Faleye B; Adepoju V; Bowale A; Adesola S; Falana A; Owuna H; Otemuyiwa K; Oladega S; Adegboye O
    Afr Health Sci; 2018 Sep; 18(3):472-478. PubMed ID: 30602977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
    Cox H; Dickson-Hall L; Ndjeka N; Van't Hoog A; Grant A; Cobelens F; Stevens W; Nicol M
    PLoS Med; 2017 Feb; 14(2):e1002238. PubMed ID: 28222095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
    Ershova JV; Volchenkov GV; Somova TR; Kuznetsova TA; Kaunetis NV; Kaminski D; Demikhova OV; Chernousova LN; Vasilyeva IA; Kerr EM; Cegielski JP; Kurbatova EV
    BMC Infect Dis; 2020 Jul; 20(1):543. PubMed ID: 32711457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Introducing Xpert MTB/RIF on Diagnosis and Treatment of Drug-Resistant Tuberculosis Patients in Indonesia: A Pre-Post Intervention Study.
    van Kampen SC; Susanto NH; Simon S; Astiti SD; Chandra R; Burhan E; Farid MN; Chittenden K; Mustikawati DE; Alisjahbana B
    PLoS One; 2015; 10(6):e0123536. PubMed ID: 26075722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting time to treatment initiation after diagnosis for multidrug-resistant/rifampicin-resistant tuberculosis patients: A mixed-methods study in Jakarta, Indonesia.
    Silitonga P; Jiang W; Wyatt S; Burhan E; Kes EFM; Long Q
    Trop Med Int Health; 2023 Jan; 28(1):43-52. PubMed ID: 36477995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda.
    Ngabonziza JS; Habimana YM; Decroo T; Migambi P; Dushime A; Mazarati JB; Rigouts L; Affolabi D; Ivan E; Meehan CJ; Van Deun A; Fissette K; Habiyambere I; Nyaruhirira AU; Turate I; Semahore JM; Ndjeka N; Muvunyi CM; Condo JU; Gasana M; Hasker E; Torrea G; de Jong BC
    Int J Tuberc Lung Dis; 2020 Mar; 24(3):329-339. PubMed ID: 32228764
    [No Abstract]   [Full Text] [Related]  

  • 13. Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes.
    Katende B; Esterhuizen TM; Dippenaar A; Warren RM
    Sci Rep; 2020 Feb; 10(1):1917. PubMed ID: 32024860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors.
    Xu C; Li R; Shewade HD; Jeyashree K; Ruan Y; Zhang C; Wang L; Zhang H
    PLoS One; 2019; 14(4):e0214943. PubMed ID: 30958841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.
    Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S
    PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
    van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S
    PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.
    De Vos E; Scott L; Voss De Lima Y; Warren RM; Stevens W; Hayes C; da Silva P; Van Rie A
    Int J Tuberc Lung Dis; 2021 Feb; 25(2):134-141. PubMed ID: 33656425
    [No Abstract]   [Full Text] [Related]  

  • 18. The Multi-Drug Resistant Tuberculosis Diagnosis and Treatment Cascade in Bangladesh.
    Hossain ST; Isaakidis P; Sagili KD; Islam S; Islam MA; Shewade HD; Kamal SM; Husain A
    PLoS One; 2015; 10(6):e0129155. PubMed ID: 26110273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study.
    Wasihun AG; Dejene TA; Hailu GG
    PLoS One; 2020; 15(11):e0240361. PubMed ID: 33147218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the impact of genotypic based diagnostic algorithm on time to treatment initiation and treatment outcomes among drug-resistant tuberculosis patients in Amhara region, Ethiopia.
    Kassa GM; Merid MW; Muluneh AG; Wolde HF
    PLoS One; 2021; 16(2):e0246938. PubMed ID: 33600409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.